MMRFX Performance — MassMutual Select T. Rowe Price Real Assets Fund, Class I
Data updated: 2025-08-25
MMRFX returned +7.09% over one year to Jun 2025. Annualised returns are +7.50% over 3 years and +10.19% over 5 years. The fund trailed its Global Mid-Cap Blend category average: $100 invested three years ago grew to $124, against $135 for the category, and to $107 over one year, against $115. Volatility over the past three years was 17.65% a year. In the 12 months to Jun 2025 the fund lost a net $224.4M, and assets reached $91.10M.
MMRFX Growth of $100
What $100 invested in MassMutual Select T. Rowe Price Real Assets Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Global Mid-Cap Blend category average over the same months.
| Period | MMRFX | Category average |
|---|---|---|
| 1 year (Jul 2024 – Jun 2025) | $107 | $115 |
| 3 years (Jul 2022 – Jun 2025) | $124 | $135 |
| 5 years (Jul 2020 – Jun 2025) | $162 | $174 |
| Since data start (Jul 2019 – Jun 2025) | $149 | $164 |
MMRFX Trailing Returns
Total returns to Jun 2025, from SEC N-PORT.
| Period | Total return |
|---|---|
| 1 year | +7.09% |
| 3 years (annualised) | +7.50% |
| 5 years (annualised) | +10.19% |
MMRFX Annual Returns
Calendar-year total returns of MassMutual Select T. Rowe Price Real Assets Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2025 (Jan–Jun) | +8.03% |
| 2024 | +0.78% |
| 2023 | +7.44% |
| 2022 | −9.63% |
| 2021 | +26.70% |
| 2020 | +5.44% |
| 2019 (Jul–Dec) | +5.21% |
MMRFX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | +0.7% | +1.4% | +2.5% | −1.7% | +2.3% | +2.5% | — | — | — | — | — | — |
| 2024 | +6.9% | +0.7% | −4.5% | −1.9% | +3.9% | −3.0% | +3.1% | +1.9% | +4.3% | −8.3% | +2.0% | −3.3% |
| 2023 | +0.1% | −5.9% | +9.1% | +5.9% | −6.8% | 0.0% | −3.8% | −4.1% | +4.9% | +6.5% | +7.0% | −3.9% |
| 2022 | +5.8% | +0.9% | −2.9% | −13.2% | +0.5% | −5.9% | −9.8% | −3.3% | +7.0% | −4.1% | +10.2% | +7.6% |
| 2021 | +3.5% | +5.9% | −1.0% | −1.6% | +4.0% | +6.1% | −4.5% | −0.4% | +2.4% | +6.0% | −2.7% | +7.1% |
| 2020 | −17.7% | −8.4% | −3.5% | +2.5% | +3.4% | +12.8% | −4.1% | +2.1% | +6.4% | +6.0% | +12.3% | −2.1% |
| 2019 | — | — | — | — | — | — | +1.6% | −1.1% | −1.5% | +4.5% | +0.4% | +1.4% |
MMRFX Risk
Risk measures from monthly returns over Jul 2022 – Jun 2025.
- 3-year volatility (annualised): 17.65%
- 3-year Sharpe ratio: 0.17 (vs 4.5% risk-free rate)
- Best month: +10.15% (Nov 2022)
- Worst month: −9.77% (Jul 2022)
MMRFX Fund Flows
Monthly money in and out of MassMutual Select T. Rowe Price Real Assets Fund, from SEC Form N-PORT.
- 12-month net flow: −$224.4M
- 12-month gross sales (incl. reinvestments): $60.3M
- Sales ÷ redemptions: 0.21×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2025 | $911K | $2.0M | −$1.1M |
| May 2025 | $2.2M | $7.6M | −$5.4M |
| Apr 2025 | $693K | $7.5M | −$6.8M |
| Mar 2025 | $16.5M | $194.9M | −$178.4M |
| Feb 2025 | $717K | $3.2M | −$2.5M |
| Jan 2025 | $2.0M | $5.9M | −$3.8M |
| Dec 2024 | $2.2M | $3.2M | −$909K |
| Nov 2024 | $2.3M | $11.0M | −$8.8M |
| Oct 2024 | $18.9M | $4.9M | $14.1M |
| Sep 2024 | $6.5M | $22.8M | −$16.3M |
| Aug 2024 | $6.1M | $12.7M | −$6.7M |
| Jul 2024 | $1.2M | $9.1M | −$7.9M |
MMRFX Assets Under Management
Net assets of MassMutual Select T. Rowe Price Real Assets Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2025-06-30 | $91.10M |
| 2025-03-31 | $100.97M |
| 2024-12-31 | $277.81M |
| 2024-09-30 | $320.57M |
| 2024-06-30 | $321.93M |
| 2024-03-31 | $398.95M |
| 2023-12-31 | $353.20M |
| 2023-09-30 | $325.61M |
| 2023-06-30 | $263.44M |
| 2023-03-31 | $244.30M |
| 2022-12-31 | $237.69M |
| 2022-09-30 | $210.34M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.